CD105 is a surface marker for receptor-targeted gene transfer into human long-term repopulating hematopoietic stem cells

Stem Cells and Development

Volumn 24, Issue 6, 2015, Pages 714-723

  Kays, Sarah Katharina ^a   Kaufmann, Kerstin B ^b,d   Abel, Tobias ^a   Brendel, Christian ^b,e   Bonig, Halvard ^c   Grez, Manuel ^b   Buchholz, Christian J ^a   Kneissl, Sabrina ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; ENDOGLIN; GRANULOCYTE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CELL SELECTION; COLONY FORMING CELL; COLONY FORMING UNIT; CONTROLLED STUDY; ENGRAFTMENT; GENE EXPRESSION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TARGET CELL; TRANSIENT TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CYTOLOGY; GENE TARGETING; GENETICS; METABOLISM; NONOBESE DIABETIC MOUSE; PROCEDURES; SCID MOUSE; STEM CELL TRANSPLANTATION;

MUS;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD34; CELL DIFFERENTIATION; GENE TARGETING; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CELL SURFACE; STEM CELL TRANSPLANTATION;

EID: 84924346983     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0455     Document Type: Article

References (45)

1. Aiuti A and MG Roncarolo. (2009). Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program 682-689. DOI: 10.1182/asheducation-2009.1.682.
2. Naldini L. (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12:301-315.
3. Kaufmann KB, H Büning, A Galy, A Schambach and M Grez. (2013). Gene therapy on the move. EMBO Mol Med 5:1642-1661.
4. Grez M, J Reichenbach, J Schwäble, R Seger, MC Dinauer and AJ Thrasher. (2011). Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 19: 28-35.
5. Guenechea G, OI Gan, C Dorrell and JE Dick. (2001). Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol 2:75-82.
6. McKenzie JL, OI Gan, M Doedens, JC Wang and JE Dick. (2006). Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol 7: 1225-1233.
7. Finkelshtein D, A Werman, D Novick, S Barak and M Rubinstein. (2013). LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110:7306-7311.
8. Amirache F, C Lévy, C Costa, P Mangeot, BE Torbett, CX Wang, D Nègre, F Cosset and E Verhoeyen. (2014). Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood 123:1422-1424.
9. Funke S, A Maisner, MD Mühlebach, U Koehl, M Grez, R Cattaneo, K Cichutek and CJ Buchholz. (2008). Targeted cell entry of lentiviral vectors. Mol Ther 16:1427-1436.
10. Kneissl S, Q Zhou, M Schwenkert, F Cosset, E Verhoeyen and CJ Buchholz. (2013). CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PLoS One 8:e79047.
11. Zhou Q, IC Schneider, I Edes, A Honegger, P Bach, K Schönfeld, A Schambach, WS Wels, S Kneissl, W Uckert and CJ Buchholz. (2012). T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood 120:4334-4342.
12. Ageichik A, CJ Buchholz and MK Collins. (2011). Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther 22:1249-1254.
13. Anliker B, T Abel, S Kneissl, J Hlavaty, A Caputi, J Brynza, IC Schneider, RC Münch, H Petznek, et al. (2010). Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods 7:929-935.
14. Abel T, E El Filali, J Waern, IC Schneider, Q Yuan, RC Münch, M Hick, G Warnecke, N Madrahimov, et al. (2013). Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood 122:2030-2038.
15. Münch RC, MD Mühlebach, T Schaser, S Kneissl, C Jost, A Plückthun, K Cichutek and CJ Buchholz. (2011). DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther 19:686-693.
16. Buchholz CJ, MD Mühlebach and K Cichutek. (2009). Lentiviral vectors with measles virus glycoproteins-dream team for gene transfer? Trends Biotechnol 27:259-265.
17. St-Jacques S, U Cymerman, N Pece and M Letarte. (1994). Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 134:2645-2657.
18. Warrington K, MC Hillarby, C Li, M Letarte and S Kumar. (2005). Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res 25: 1851-1864.
19. Chen C, M Li, D de Graaf, S Monti, B Göttgens, M Sanchez, ES Lander, TR Golub, AR Green and HF Lodish. (2002). Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A 99:15468-15473.
20. Chen C, L Li, M Li and HF Lodish. (2003). The endoglin(positive) sca-1(positive) rhodamine(low) phenotype defines a near-homogeneous population of long-term repopulating hematopoietic stem cells. Immunity 19:525-533.
21. Roques M, C Durand, R Gautier, P Canto, L Petit-Cocault, L Yvernogeau, D Dunon, M Souyri and T Jaffredo. (2012). Endoglin expression level discriminates long-term hematopoietic from short-term clonogenic progenitor cells in the aorta. Haematologica 97:975-979.
22. Pierelli L, G Scambia, G Bonanno, S Rutella, P Puggioni, A Battaglia, S Mozzetti, M Marone, G Menichella, et al. (2000). CD34 +/CD105 + cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34 +/CD38low/- precursors. Br J Haematol 108:610-620.
23. Pierelli L, G Bonanno, S Rutella, M Marone, G Scambia and G Leone. (2001). CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma 42: 1195-1206.
24. Kneissl S, T Abel, A Rasbach, J Brynza, J Schneider-Schaulies and CJ Buchholz. (2012). Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One 7:e46667.
25. Zufferey R, D Nagy, RJ Mandel, L Naldini and D Trono. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875.
26. Demaison C, K Parsley, G Brouns, M Scherr, K Battmer, C Kinnon, M Grez and AJ Thrasher. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13:803-813.
27. Brehm MA, LD Shultz, J Luban and DL Greiner. (2013). Overcoming current limitations in humanized mouse research. J Infect Dis 208 (Suppl 2):S125-S130.
28. Nassiri F, MD Cusimano, BW Scheithauer, F Rotondo, A Fazio, GM Yousef, LV Syro, K Kovacs and RV Lloyd. (2011). Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res 31:2283-2290.
29. Hatzfeld J, ML Li, EL Brown, H Sookdeo, JP Levesque, T O'Toole, C Gurney, SC Clark and A Hatzfeld. (1991). Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. J Exp Med 174:925-929.
30. Aiuti A, L Biasco, S Scaramuzza, F Ferrua, MP Cicalese, C Baricordi, F Dionisio, A Calabria, S Giannelli, et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341:123-151.
31. Biffi A, E Montini, L Lorioli, M Cesani, F Fumagalli, T Plati, C Baldoli, S Martino, A Calabria, et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:1233158.
32. Cartier N, S Hacein-Bey-Abina, CC Bartholomae, G Veres, M Schmidt, I Kutschera, M Vidaud, U Abel, L Dal-Cortivo, et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:818-823.
33. Géronimi F, E Richard, I Redonnet-Vernhet, I Lamrissi-Garcia, M Lalanne, C Ged, F Moreau-Gaudry and H de Verneuil. (2003). Highly efficient lentiviral gene transfer in CD34 + and CD34 +/38-/lin-cells from mobilized peripheral blood after cytokine prestimulation. Stem Cells 21: 472-480.
34. Ailles L, M Schmidt, FR Santoni de Sio, H Glimm, S Cavalieri, S Bruno, W Piacibello, C von Kalle and L Naldini. (2002). Molecular evidence of lentiviral vectormediated gene transfer into human self-renewing, multipotent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther 6:615-626.
35. Amsellem S, E Ravet, S Fichelson, F Pflumio and A Dubart-Kupperschmitt. (2002). Maximal lentivirus-mediated gene transfer and sustained transgene expression in human hematopoietic primitive cells and their progeny. Mol Ther 6:673-677.
36. Knight S, M Collins and Y Takeuchi. (2013). Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr Gene Ther 13:211-227.
37. Glimm H, IH Oh and CJ Eaves. (2000). Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood 96:4185-4193.
38. Kittler EL, SO Peters, RB Crittenden, ME Debatis, HS Ramshaw, FM Stewart and PJ Quesenberry. (1997). Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts. Blood 90:865-872.
39. Hanawa H, PF Kelly, AC Nathwani, DA Persons, JA Vandergriff, P Hargrove, EF Vanin and AW Nienhuis. (2002). Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5:242-251.
40. Bell AJ, D Fegen, M Ward and A Bank. (2010). RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors. Exp Biol Med 235: 1269-1276.
41. Verhoeyen E, M Wiznerowicz, D Olivier, B Izac, D Trono, A Dubart-Kupperschmitt and F Cosset. (2005). Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood 106: 3386-3395.
42. Frecha C, C Costa, D Nègre, F Amirache, D Trono, P Rio, J Bueren, F Cosset and E Verhoeyen. (2012). A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood 119:1139-1150.
43. Girard-Gagnepain A, F Amirache, C Costa, C Lévy, C Frecha, F Fusil, D Nègre, D Lavillette, F Cosset and E Verhoeyen. (2014). Baboon envelope pseudotyped lentiviral vectors outperform VSV-G pseudotyped lentiviral vectors for gene transfer into cytokine-stimulated and resting hematopoietic stem cells. Blood 124:1221-1231.
44. Brendel C, B Goebel, D Abriß, M Brugman, S Kneissl, J Schwäble, KB Kaufmann, U Müller-Kuller, H Kunkel, et al. (2015). CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells. Mol Ther 23:63-70.
45. Lin C, Z Xin, J Dai and TF Lue. (2013). Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges. Histol Histopathol 28:1109-1116.